{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:43Z","timestamp":1707524923774},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,20]]},"DOI":"10.7759\/cureus.35220","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:22:09Z","timestamp":1676910129000},"source":"Crossref","is-referenced-by-count":0,"title":["A Cardiologists\u2019 Survey on the Use of Anticoagulants and Antiplatelets in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Those Undergoing Percutaneous Coronary Intervention in India"],"prefix":"10.7759","author":[{"given":"Namrata","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Taur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravishankar","family":"Akolekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swetha","family":"ES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Atrial fibrillation","author":"Nesheiwat ZGA","year":"2021","unstructured":"Nesheiwat ZGA, Jagtap M. Atrial fibrillation. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euz033","article-title":"Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey","volume":"21","author":"Lane DA","year":"2019","unstructured":"Lane DA, Dagres N, Dan GA, et al.. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Europace. 2019, 21:1116-25. 10.1093\/europace\/euz033","journal-title":"Europace"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2048872615610868","article-title":"Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents","volume":"6","author":"Steg PG","year":"2017","unstructured":"Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care. 2017, 6:93-7. 10.1177\/2048872615610868","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January CT","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al.. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019, 74:104-32. 10.1016\/j.jacc.2019.01.011","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam EA","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al.. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014, 64:e139-228. 10.1016\/j.jacc.2014.09.017","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara PT","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, et al.. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, 61:e78-e140. 10.1016\/j.jacc.2012.11.019","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes RD","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, et al.. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019, 380:1509-24. 10.1056\/NEJMoa1817083","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel H","year":"2015","unstructured":"Heidbuchel H, Verhamme P, Alings M, et al.. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015, 17:1467-507. 10.1093\/europace\/euv309","journal-title":"Europace"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2019.05.008","article-title":"Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome","volume":"30","author":"Deharo P","year":"2020","unstructured":"Deharo P, Cuisset T. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends Cardiovasc Med. 2020, 30:198-202. 10.1016\/j.tcm.2019.05.008","journal-title":"Trends Cardiovasc Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041120","article-title":"Non-vitamin K oral anticoagulants (NOAC) versus vitamin K antagonists (VKA) for atrial fibrillation with elective or urgent percutaneous coronary intervention: a meta-analysis with a particular focus on combination type","volume":"9","author":"Eyileten C","year":"2020","unstructured":"Eyileten C, Postula M, Jakubik D, et al.. Non-vitamin K oral anticoagulants (NOAC) versus vitamin K antagonists (VKA) for atrial fibrillation with elective or urgent percutaneous coronary intervention: a meta-analysis with a particular focus on combination type. J Clin Med. 2020, 9:1120. 10.3390\/jcm9041120","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen ML","year":"2010","unstructured":"Hansen ML, S\u00f8rensen R, Clausen MT, et al.. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010, 170:1433-41. 10.1001\/archinternmed.2010.271","journal-title":"Arch Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.12.026","article-title":"Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease","volume":"129","author":"Lopes RD","year":"2016","unstructured":"Lopes RD, Rao M, Simon DN, et al.. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Am J Med. 2016, 129:592-9.e1. 10.1016\/j.amjmed.2015.12.026","journal-title":"Am J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen R","year":"2009","unstructured":"S\u00f8rensen R, Hansen ML, Abildstrom SZ, et al.. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009, 374:1967-74. 10.1016\/S0140-6736(09)61751-7","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2018.03.001","article-title":"An open-Label, 2 \u00d7 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial","volume":"200","author":"Lopes RD","year":"2018","unstructured":"Lopes RD, Vora AN, Liaw D, et al.. An open-Label, 2 \u00d7 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and\/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J. 2018, 200:17-23. 10.1016\/j.ahj.2018.03.001","journal-title":"Am Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson CM","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, et al.. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016, 375:2423-34. 10.1056\/NEJMoa1611594","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon CP","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, et al.. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017, 377:1513-24. 10.1056\/NEJMoa1708454","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000032181.98320.8D","article-title":"Physician utilization the state of research about physicians' practice patterns","volume":"40","author":"Eisenberg JM","year":"2002","unstructured":"Eisenberg JM. Physician utilization the state of research about physicians' practice patterns. Medical care. 2002, 40:1016-35. 10.1097\/01.MLR.0000032181.98320.8D","journal-title":"Medical care"},{"key":"ref18","unstructured":"Cardiology ACo. Global Anticoagulation Therapy Patterns Vary. Findings from TREAT-RISK. (2021). Accessed: September 14, 2021: http:\/\/www.acc.org\/latest-in-cardiology\/articles\/2012\/10\/19\/16\/38\/global-anticoagulation-therapy-patterns-vary."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Kumbhani DJ","year":"2021","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ, et al.. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021, 77:629-58. 10.1016\/j.jacc.2020.09.011","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1313210","article-title":"Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation","volume":"33","author":"Potpara TS","year":"2017","unstructured":"Potpara TS, Boriani G, Lip GY. Evaluating adherence to non-vitamin-K antagonist oral anticoagulants in post-approval observational studies of patients with atrial fibrillation. Curr Med Res Opin. 2017, 33:1175-7. 10.1080\/03007995.2017.1313210","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-016-0185-9","article-title":"Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review","volume":"10","author":"Wilke T","year":"2017","unstructured":"Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient preferences for oral anticoagulation therapy in atrial fibrillation: a systematic literature review. Patient. 2017, 10:17-37. 10.1007\/s40271-016-0185-9","journal-title":"Patient"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvw048","article-title":"Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists","volume":"3","author":"S\u00f8rensen R","year":"2017","unstructured":"S\u00f8rensen R, Jamie Nielsen B, Langtved Pallisgaard J, Ji-Young Lee C, Torp-Pedersen C. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. Eur Heart J Cardiovasc Pharmacother. 2017, 3:151-6. 10.1093\/ehjcvp\/pvw048","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73871-x","article-title":"Efficacy and safety of newer P2Y(12) inhibitors for acute coronary syndrome: a network meta-analysis","volume":"10","author":"Fei Y","year":"2020","unstructured":"Fei Y, Lam CK, Cheung BM. Efficacy and safety of newer P2Y(12) inhibitors for acute coronary syndrome: a network meta-analysis. Sci Rep. 2020, 10:16794. 10.1038\/s41598-020-73871-x","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel J","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, et al.. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018, 39:1330-93. 10.1093\/eurheartj\/ehy136","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip GY","year":"2019","unstructured":"Lip GY, Collet JP, Haude M, et al.. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019, 21:192-3. 10.1093\/europace\/euy174","journal-title":"Europace"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli M","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al.. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018, 53:34-78. 10.1093\/ejcts\/ezx334","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvasa.2016.11.005","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"6","author":"\u010cih\u00e1k R","year":"2016","unstructured":"\u010cih\u00e1k R, Haman L, T\u00e1borsk\u00fd M. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Cor et vasa. 2016, 6:636-83. 10.1016\/j.crvasa.2016.11.005","journal-title":"Cor et vasa"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo DJ","year":"2021","unstructured":"Angiolillo DJ, Bhatt DL, Cannon CP, et al.. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update. Circulation. 2021, 143:583-96. 10.1161\/CIRCULATIONAHA.120.050438","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1719081","article-title":"Novel dual therapy: a paradigm shift in anticoagulation in patients of atrial fibrillation undergoing percutaneous coronary intervention","volume":"4","author":"Pradhan A","year":"2020","unstructured":"Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Novel dual therapy: a paradigm shift in anticoagulation in patients of atrial fibrillation undergoing percutaneous coronary intervention. TH Open. 2020, 4:e332-43. 10.1055\/s-0040-1719081","journal-title":"TH Open"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and cons of new oral anticoagulants","volume":"2013","author":"Bauer KA","year":"2013","unstructured":"Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013, 2013:464-70. 10.1182\/asheducation-2013.1.464","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2015-000279","article-title":"NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis","volume":"3","author":"Hicks T","year":"2016","unstructured":"Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart. 2016, 3:e000279. 10.1136\/openhrt-2015-000279","journal-title":"Open Heart"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22750","article-title":"Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events","volume":"40","author":"Lemesle G","year":"2017","unstructured":"Lemesle G, Ducrocq G, Elbez Y, et al.. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events. Clin Cardiol. 2017, 40:932-9. 10.1002\/clc.22750","journal-title":"Clin Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj YH","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015, 11:967-77. 10.2147\/TCRM.S84210","journal-title":"Ther Clin Risk Manag"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander JH","year":"2014","unstructured":"Alexander JH, Lopes RD, Thomas L, et al.. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014, 35:224-32. 10.1093\/eurheartj\/eht445","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick M","year":"2020","unstructured":"Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020, 172:463-73. 10.7326\/M19-2522","journal-title":"Ann Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz086","article-title":"Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study","volume":"6","author":"Rutherford OW","year":"2020","unstructured":"Rutherford OW, Jonasson C, Ghanima W, S\u00f6derdahl F, Halvorsen S. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020, 6:75-85. 10.1093\/ehjcvp\/pvz086","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/134164-a-cardiologists-survey-on-the-use-of-anticoagulants-and-antiplatelets-in-patients-with-atrial-fibrillation-and-acute-coronary-syndrome-or-those-undergoing-percutaneous-coronary-intervention-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:25Z","timestamp":1707508345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/134164-a-cardiologists-survey-on-the-use-of-anticoagulants-and-antiplatelets-in-patients-with-atrial-fibrillation-and-acute-coronary-syndrome-or-those-undergoing-percutaneous-coronary-intervention-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.35220","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,20]]}}}